Forte Biosciences (FBRX) Non-cash Items (2017 - 2026)
Forte Biosciences (FBRX) reported Non-cash Items of $952499.0 for Q1 2026, up 363.51% year-over-year from $205495.0 in Q1 2025, and down 97.98% quarter-over-quarter from $47.1 million in Q4 2025.
Forte Biosciences (FBRX) Non-cash Items (2017 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 10 years of Non-cash Items data on file, last reported at $952499.0 in Q1 2026.
- Non-cash Items for Q1 2026 came in at $952499.0, up 363.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $952499.0 (up 363.51% YoY), and the FY2025 annual result was $47.1 million, up 68415.2% from the prior year.
- Non-cash Items slipped to $952499.0 in Q1 2026 per FBRX's latest filing, from $47.1 million in the prior quarter.
- Over five years, Non-cash Items peaked at $47.1 million in Q4 2025 and troughed at $3000.0 in Q3 2023.
- A 5-year average of $4.9 million and a median of $287029.0 in 2022 frame the typical range for Non-cash Items.
- The sharpest annual moves came in 2023 and 2025: Non-cash Items plunged 99.96% in 2023, then jumped 27636.45% in 2025.
- A 5-year view of Non-cash Items shows it stood at $65000.0 in 2022, then slumped by 53.85% to $30000.0 in 2023, then jumped by 2433.33% to $760000.0 in 2024, then soared by 6093.68% to $47.1 million in 2025, then sank by 97.98% to $952499.0 in 2026.
- Business Quant data shows FBRX's Non-cash Items at $952499.0 in Q1 2026, $47.1 million in Q4 2025, and $17.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952,499.00 |
| Mar 31, 2026 | 952,499.00 |
| Dec 31, 2025 | 47.07 Mn |
| Dec 31, 2025 | 47.07 Mn |
| Sep 30, 2025 | 17.41 Mn |
| Sep 30, 2025 | 17.41 Mn |
| Jun 30, 2025 | 388,729.00 |
| Jun 30, 2025 | 388,729.00 |
| Mar 31, 2025 | 205,495.00 |
| Mar 31, 2025 | 205,495.00 |
| Dec 31, 2024 | 760,000.00 |
| Dec 31, 2024 | 760,000.00 |
| Sep 30, 2024 | 62,773.00 |
| Sep 30, 2024 | 62,773.00 |
| Jun 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |